drugset / Trial / NCT01976507
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
Timeline
- Start
- 2013-10
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 75 mg | — |
| Subject | Dabigatran etexilate | Unknown | 150 mg | — |